Introduction
Disease clearance (a composite of clinical, endoscopic, and histologic remission) may be associated with improved long-term outcomes and disease modification in ulcerative colitis (UC).1 The VERDICT study (NCT04259138) is a prospective comparison of treatments targeting corticosteroid-free (CSF) disease clearance to CSF symptomatic remission, featuring algorithms based on early introduction of vedolizumab (VDZ). Treatment target groups include CSF symptomatic remission (Mayo rectal bleeding subscore=0) (Group 1), CSF symptomatic+endoscopic remission (Mayo endoscopic subscore≤1) (Group 2), and CSF disease clearance (Geboes score<2B.0) (Group 3).
Aims & Methods
We characterized serum protein signatures in bionaïve Group 3 patients according to target achieved by week 16 (W16) and mapped to their potential cellular source. Colonic biopsies and serum samples were collected at baseline and W16. Differential gene and protein expression analyses were performed using DESeq2 and limma.2 Transcriptomic analyses included gene co-expression network (GCN) module identification. Pathway enrichment analyses for both datasets were conducted using clusterProfiler with gene set variation analysis or GSEA, leveraging Molecular Signatures Database Hallmark and Reactome pathways. Cell-type enrichment analyses mapped genes and proteins to their putative cellular origins using a human UC single-cell atlas.3
Results
As of 29 Feb 2024, baseline and W16 biopsy samples were available from 122 patients and serum samples from 154 patients across remission groups (symptomatic remission, symptomatic+endoscopic remission, disease clearance, and non-remitters [NR]); baseline characteristics were similar between groups (Table). Minimal changes from baseline to W16 were observed in NR (265 genes, 19 proteins) and symptomatic remission (432 genes, 37proteins) whereas disease clearance was associated with extensive molecular remodeling, including >10,000 differentially expressed genes and 426 proteins (p-value 0.01), characterized by downregulation of core inflammatory pathways and upregulation of immunometabolic programs. The magnitude of transcriptomic and proteomic changes was smaller in other remission groups.
At W16, patients with disease clearance were distinguished by 120 GCN transcriptional modules. Among gene–protein overlaps mapping to transcriptomic modules, concordance was observed in downregulated results indicating resolution of inflammatory programs, with emphasis on innate (neutrophil/myeloid), adaptive (T/B cell), and acute-phase responses, alongside reduced epithelial hyperproliferation. Concordant upregulated results highlighted restoration of mucosal homeostasis, including epithelial repair, barrier integrity, and neural signaling.
Conclusion
Distinct transcriptomic and proteomic signatures were observed in bionaïve UC patients achieving CSF disease clearance in response to VDZ by W16. These coordinated molecular changes may enable identification of novel biomarkers to predict early disease clearance and inform next-generation therapeutic targets.
Table. Demographics and clinical characteristics for Group 3, bionaïve, corticosteroid-free patients according to outcome achieved by week 16a,b,c with biopsy transcriptomic and serum proteomic data analyzed
|
|---|
Abbreviations: BMI, body mass index; SD, standard deviation; TNF, tumour necrosis factor; UC, ulcerative colitis. a: Data are based on in-stream data that have not been reconciled; data reconciliation will occur prior to final database lock. b: Group 3: treatment target assessed as corticosteroid-free symptomatic remission (Mayo rectal bleeding subscore=0) + endoscopic improvement (Mayo endoscopic subscore <=1) + histologic remission (Geboes score <2.B.0). c: Bionaïve is defined as no prior biologic (algorithm A) or >5 years since prior biologic use (algorithm B). |
|
| Non-remitter (N=30)
| Symptomatic remission (N=21)
| Symptomatic + endoscopic remission (N=6)
| Disease clearance (symptomatic + endoscopic +histologic remission) (N=68)
| Total (N=125) |
| Age, mean (SD) |
| 41.8 (12.65)
| 39.2 (11.88)
| 45.8 (10.91)
| 40.1 (13.32)
| 40.6 (12.76)
|
| Sex, male |
| 18 (60.0%)
| 11 (52.4%)
| 3 (50.0%)
| 36 (52.9%)
| 68 (54.4%)
|
| BMI, mean (SD) |
| 25.72 (5.382)
| 24.95 (5.098)
| 25.29 (2.762)
| 26.11 (4.990)
| 25.78 (4.992)
|
| Corticosteroid use at screening |
| 11 (36.7%)
| 10 (47.6%)
| 3 (50.0%)
| 36 (52.9%)
| 60 (48.0%)
|
| Treatment algorithm at baseline | A: Patients Not on UC Therapy | 0 (0.0%)
| 0 (0.0%)
| 0 (0.0%)
| 1 (1.5%)
| 1 (0.8%)
|
| B: Patients on Nonbiologic UC Therapies
| 30 (100.0%)
| 21 (100.0%)
| 6 (100.0%)
| 67 (98.5%)
| 124 (99.2%)
|
| C: Patients on Anti-TNF, Tofacitinib or Ustekinumab
| 0 (0.0%)
| 0 (0.0%)
| 0 (0.0%)
| 0 (0.0%)
| 0 (0.0%)
|
References
1. Danese S, et al. JCC. 2021;15(Suppl1):S305.
2. Ritchie, ME et al. Nucleic Acids Res. 2015;43:e47
3. Smillie CS, et al. Cell. 2019;178:714.
Disclosure
Funding: This work was sponsored by Takeda Development Center Americas, Inc.
SM: Grants: Genentech, Brystol Myers Squib (BMS)Personal Fees: AbbVie, Adacyte, Alimentiv, Atticus, Brystol Myers Squib (BMS), Cabaletta, Georgia Immune, Merck, Novartis; NP: Grants: Takeda, BMS, Pfizer, Astra-Zeneca, Personal Fees: Abbvie, Abivax, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Celltrion, Dr Falk Pharma UK Ltd, Ferring, Galapagos, GSK, Janssen, MSD, Roche, Pfizer, Sobi, Takeda, Tillotts; MDP: Employee of Takeda and holds stock/options in Takeda; MSS: Consulting, speaker, advisory board fees: Takeda; CH-R: None; LPB: Personal fees: Alimentiv Inc., Takeda; JFC: Research grants, payment for lectures, consulting fees: Takeda; GRD: Consultant and/or speaker fees: Alimentiv Inc., Takeda; GWM: Consultant: Alimentiv Inc.; SS: Research grants: Takeda, personal fees for speaker role, advisory board meetings (outside the submitted work): Takeda; ST: Grants/research support, consulting fees, speaker fees: Takeda; MF, LM, JP, BS, MIS, WT: Employees of Alimentiv Inc.; VA, BS, CA, SF, PP: Employees of Takeda and holds stock/options in Takeda; SS: Consultancy and personal fees: AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, Dr Falk, Ferring, Fresenius, Gilead, HIKMA, IMAB, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda, and Ventyx; VP: Consulting/advisory board fees: Alimentiv Inc. (formerly Robarts Clinical Trials), Takeda; speaker fees: Takeda.